NCT05845151

Fibroblast Activating Protein Inhibitor PET Imaging in Lupus Nephritis

Fibroblast Activating Protein Inhibitor PET Imaging for Molecular Assessment of Fibroblast Activation and Risk Evaluation in Patients With Lupus Nephritis

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Abnormal high expression of fibroblast activating protein (FAP) has been found in inflammatory reactions and benign fibrosis tissue. Autoimmune nephropathy such as lupus nephritis (LN) can lead to tubular atrophy and excessive deposition of extracellular matrix, which may be accompanied by abnormally increased expression of activated FAP in kidney tissue, and lead to renal fibrosis and long-term renal failure. This makes 68Ga-labeled FAP inhibitor (FAPI) positron emission tomography (PET) imaging the potential to early assess disease severity, predict disease progress and aid treatment planning in patients with LN. Compared to renal pathological puncture, 68Ga-FAPI PET is a new tool for non-invasive, repeatable assessment of renal fibrotic activation.

Conditions

• Lupus Nephritis

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	68Ga-FAPI-04 PET	Activation of renal fibroblast is quantified using 68Ga-FAPI-04 PET in patients with LN.

Timeline

• Start date: 2021-05-01
• Primary completion: 2023-12-31
• Completion: 2024-04-30
• First posted: 2023-05-06
• Last updated: 2023-05-06

Locations

1 site across 1 country: China